Quantcast

Latest Genomic Health Inc. Stories

2014-05-20 16:27:05

New Analysis Suggests Oncotype DX Predicts Recurrence Risk After Prostatectomy Regardless of Post-Surgery Treatment REDWOOD CITY, Calif., May 20, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today presented positive results reinforcing the robustness of the Oncotype DX(®) prostate cancer test's development as a predictor of prostate cancer aggressiveness. A sub-analysis of a large Oncotype DX Genomic Prostate Score (GPS) development study, presented at the American...

2014-05-16 16:24:58

Oncotype DX® Prostate Cancer Test Enables More Precise Risk Assessment and Significantly Increases Number of Low-Risk Patients Who Can Confidently Choose Active Surveillance REDWOOD CITY, Calif., May 16, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) announced today that groundbreaking results from three studies of the Oncotype DX(®) prostate cancer test were published in European Urology. The peer-reviewed publication highlights studies that focus on addressing the need...

2014-05-14 08:31:12

Centralized database of gene-based tests enables easy access to information, improves transparency REDWOOD CITY, Calif., May 14, 2014 /PRNewswire/ -- In response to continued advances in genomic technology and genetic medicine, the National Institutes of Health (NIH) has developed the Genetic Testing Registry (GTR), a free online resource, to provide physicians, researchers and patients with detailed and accurate information about genetic and genomic tests. Comprehensive scientific...

2014-05-06 16:32:54

13% Increase in Test Volume and 7% Increase in Product Revenue Compared to Prior Year REDWOOD CITY, Calif., May 6, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter ended March 31, 2014. Logo - http://photos.prnewswire.com/prnh/20130425/SF01493LOGO Product revenue was $67.0 million in the first quarter of 2014, compared with $62.7 million for the first quarter of 2013, an increase of 7 percent. Total revenue for...

2014-05-05 20:25:53

LONDON, May 5, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Molecular Diagnostics in Cancer Testinghttp://www.reportbuyer.com/pharma_healthcare/diagnostics/molecular_diagnostics_cancer_testing.htmlMolecular diagnostics is a rapidly-advancing area of research and medicine, with new technologies and applications being continually added. The technologies that come under the umbrella of molecular diagnostics include first-generation amplification, DNA...

2014-05-05 08:28:31

New Data Include Results on Oncotype DX's Prognosis of Late Recurrence in Invasive Breast Cancer and Clinical Utility in Ductal Carcinoma In Situ (DCIS) REDWOOD CITY, Calif., May 5, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that results from nine studies of Oncotype DX(®) in breast, colon, prostate and renal cancer will be presented at the American Society of Clinical Oncology(®) (ASCO(®)) Annual Meeting, taking place May 30 - June 3, 2014 at McCormick Place...

2014-05-02 08:25:16

Large Study Published in The Oncologist Underscores Test's Value in Guiding Treatment Decisions REDWOOD CITY, Calif., May 2, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that The Oncologist published positive results from an Oncotype DX(®) colon cancer decision impact study, demonstrating that Recurrence Score(®) results changed treatment recommendations in 45 percent of stage II colon cancer patients. The study was conducted in collaboration with the...

2014-04-29 08:35:57

REDWOOD CITY, Calif., April 29, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will host a conference call and webcast on Tuesday, May 6 at 4:30 p.m. Eastern Time to discuss its first quarter 2014 financial results. The call and webcast will follow the release of the first quarter financial results after market close. http://photos.prnewswire.com/prnvar/20130425/SF01493LOGO Conference Call DetailsTo access the live conference call on May 6...

2014-04-22 08:33:21

Expanded Reimbursement in Canada and Inclusion in Leading German Physician Guidelines Increase Genomic Health's Impact in Key International Markets REDWOOD CITY, Calif., April 22, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced two important international milestones including additional reimbursement in Canada and the inclusion of the Oncotype DX(®) breast cancer test in major German clinical guidelines. In Canada, the BC Cancer Agency in British Columbia...

2014-03-19 08:29:07

Data Presented at 9th European Breast Cancer (EBCC-9) Symposium Highlights Comprehensive Body of Clinical Evidence for Oncotype DX REDWOOD CITY, Calif., March 19, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the presentation of multiple Oncotype DX® breast cancer studies at the 9(th) European Breast Cancer Conference (EBCC-9), which takes place March 19-21 in Glasgow, Scotland, United Kingdom. New data will include an independently conducted physician survey that...


Word of the Day
barratry
  • The offense of persistently instigating lawsuits, typically groundless ones.
  • An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
  • Sale or purchase of positions in church or state.
This word ultimately comes from the Old French word 'barater,' to cheat.
Related